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BODY

The Specific Aim of this application is to identify genetic risk alleles for breast cancer among African American women by performing a well-powered genome-wide association study (GWAS).
For this project, I have established a network of leaders in the breast cancer research community with long-standing interests in breast cancer research in African Americans, all of whom have existing case-control studies of breast cancer in the U.S. Funding for the genotyping of samples from the MEC, CARE, WCHS, SFBC and BCFR studies is covered by this DOD-BCRP grant. The genotyping of the other studies has been provided by a number of other sources. All together these studies include over 5,000 African American women with invasive breast cancer and over 5,000 age-matched African American controls with available DNA.
Stage 1 of the GWAS included 9 epidemiological studies of invasive breast cancer among African American women, which comprise a total of 3,153 cases and 2,831 controls. Replication testing of the top associations is being conducted (using other sources) in an independent sample of >2000 African American breast cancer cases and >2000 controls from three additional studies of breast cancer (discussed below). Below is a brief description of these 12 studies.
Stage 1 Studies: The Multiethnic Cohort Study (MEC):
The MEC is a prospective cohort study of 215,000 men and women in Hawaii and Los Angeles between the ages of 45 and 75 years at baseline (1993) (1994) (1995) (1996) 
Genotyping and Quality Control
Genotyping in stage 1 was conducted using the Illumina Human1M-Duo BeadChip. Of the 5,984 samples from these studies (3,153 cases and 2,831 controls), we attempted genotyping of 5,932, removing samples (n=52) with DNA concentrations <20 ng/ul. Following genotyping, we removed samples based on the following exclusion criteria: 1) unknown replicates (≥98.9% genetically identical) that we were able to confirm (only one of each duplicate was removed, n=15); 2) unknown replicates that we were not able to confirm through discussions with study investigators (pair or triplicate removed, n=14); 3) samples with call rates <95% after a second attempt (n=100); 4) samples with ≤ 5% African ancestry (n=36); and, 5) samples with <15% mean heterozygosity of SNPs in the X chromosome and/or similar mean allele intensities of SNPs on the X and Y chromosomes (n=6) (these are likely to be males ) were noted. We also applied principal components analysis (PCA) (2) to estimate axes of variation among the 5,761 individuals using the same 2,546 ancestry informative markers. The first eigenvector accounted for 10.1% of the variation between subjects, and subsequent eigenvectors accounted for no more than 0.5%. Using input genotypes from the HapMap populations, CEU (CEPH Utah), YRI (Yoruba), and JPT (Japanese), we could demonstrate that the first eigenvector captures most of the genetic variation in the stage 1 sample as well as that between Europeans and West Africans in the HapMap samples. In the single SNP analyses, we examined the observed versus the expected distribution of the Chi squared test statistics from the 1 degree of freedom (df) trend test, comparing genotype counts in all cases and controls, and stratified by the ER status of the tumor. To improve coverage, we augmented the set of SNPs tested for association through imputation using MACH (3). Phased haplotypes from the African American (ASW) population of HapMap Phase 3 were used to infer all Phase 3 genotypes available in this population which corresponds to the SNPs on either of the Illumina 1M or Affymetrix 6.0 arrays. For each imputed SNP, we opted to make use of genotype dosage scores, which are coded as continuous variables, thus implicitly incorporating uncertainty to help improve statistical power, control bias in risk estimation, and improve confidence interval estimation (relative to using the "most likely" genotype). Odds ratios (OR) and 95% confidence intervals (CI) for each SNP were estimated using unconditional logistic regression, adjusting for age at diagnosis, the first eigenvector and study. For each SNP we tested significance through a one degree of freedom (df) Wald chi-square test.
Stage 1 Results
As presented in the previous progress report (2009), the quantile-quantile plot demonstrates only a very slight excess of associations at p<0.05 than what would be expected based on chance, especially in the 10 -3 to 10 -5 range. No SNP association was observed at the genomewide level of significance (p<10 -7 ). We are currently following-up the 100 top associations in the replication studies (in addition to the chromosome 5q31 locus described in the 2009 progress report). We expect the genotyping to be complete in the Fall of 2010.
Testing of Known Breast Cancer Risk Variants
Using the African American cases and controls from stage 1, we also examined associations with 11 loci identified in previous GWAS in populations of European ancestry (4-8) and 1 in Chinese (9). We had good statistical power (range: >99% -69%) to detect nominally significant associations (p<0.05) for eight of the twelve established risk variants. Ten of the markers were on the Illumina Human1M-Duo BeadChip, whereas close proxies were identified for the other two loci (6q25 and 17q22). Only two variants (Table 1) were found to be nominally associated with risk among African Americans (rs13387042 at 2q35: OR=1.12, p=8.8x10 -3 ; and, rs10736303 (FGFR2) on 10q26, OR=1.15; p=8.3x10 -3 ). These data suggest that most of the index signals at the established breast cancer GWAS loci may be poor risk markers for African Americans.
Meta-Analyses with other Breast Cancer GWAS
We have also initiated meta-analyses with other GWAS including a GWAS of triple negative breast cancer (PI, Fergus Couch), a GWAS of bilateral breast cancer (Julian Peto), and a GWAS of estrogen receptor negative breast from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). SNPs from our scan in African American women that replicate in these additional studies among women of European ancestry will be targeted for follow-up in other studies (such as the African American replication studies mentioned above). In addition, we have provided the top 5000 SNPs from the African American breast cancer scan to COGs, a European collaborative study which is has designed a SNP array with that will be genotyped in 10,000's of breast cancer cases and 10,000's of controls. This collaboration will allow for very large-scale replication of findings from our African American breast cancer scan. 
Multiethnic Fine-Mapping
Genome-wide association studies (GWAS) have been conducted primarily in single racial/ethnic populations. These discovery efforts have focused on discrete, rather than multiple populations of different ancestries, to avoid false-positive signals and the potential masking of real associations resulting from population differences in allele frequencies, patterns of linkage disequilibrium (LD) and genetic and environmental modifiers. GWAS and fine-mapping studies that include multiple racial and ethnic populations allow for the assessment of a much wider spectrum of genetic variation and offer great power to detect risk variants that are common globally. We have combined our GWAS data in African Americans with existing breast cancer GWAS data among Chinese and European American women and conducted multiethnic mapping to search for novel risk variants at the known breast cancer susceptibility loci. Below are our results for the risk locus on chromosome 2q35. A GWAS among Icelandic individuals conducted by deCODE Genetics (5) initially identified an association with variant rs13387042 (position 217,614,077 NCBI Build 36; OR=1.2 per copy of the A allele) on chromosome 2q35 that has since been replicated in a number of additional studies in diverse samples. The variant is located in an 85 kb LD block, with the nearest known genes being TNP1, IGFBP2 and IGFBP1 located between 181 and 376 kb centromeric to the index signal and TNS1 781 kb telomeric. We conducted a meta-analysis of , including the previously published variant (rs13387042, p=5.6x10 -4 ). The associations with these SNPs were much stronger in African American and Europeans, than in Chinese. The risk-associated markers were correlated (r 2 ≥0.25, CEU HapMap) and no secondary signals were noted with these 15 markers when conditioning on rs13387042.
We observed a second region of association (region 2) located ~400 kb centromeric to region 1 (Figure 1 . These SNPs reside in a separate LD block of ~160 kb that is located ~330 kb from the nearest gene, TNS1. The associations with these SNPs were generally consistent and nominally significant in most populations. The 13 SNPs were correlated (r 
Enhancing the interpretation of GWAS results through local ancestry information
Software developed by our collaborators at the Broad Institute in Boston (Alkes Price) has allowed us to better understand the genetic basis behind racial disparities in the prevalence of ER/PR negative forms of breast cancer. The program ancestrymap was designed to detect regions of the genome that harbored a greater proportion of alleles from one ancestral population than the expected proportion (averaged across the genome). Although designed for coarse marker panels, we applied the method on our African American breast cancer dataset, revealing a wide peak of local ancestry deviation at Chromosome 10 in the region of FGFR2, a known breast cancer susceptibility locus. We have recently applied a newer program called hapmix that is optimized for use in high-density SNP panels (e.g. Illumina Infinium products) to the same dataset. We have narrowed the peak at Chromosome 10 and revealed other smaller peaks elsewhere. Currently, we are applying a method that is still under development at the Broad with the goal of combining signals from a case-only admixture mapping method (i.e., output from hapmix) with p-values from a GWAS that uses cases and controls. The method is expected to yield greater power over one that relies on conventional GWAS p-values since the statistic is based on a 1 df test that uses additional information about local ancestry.
Discovery of pathway-level gene or interaction (e.g. gene by gene, gene by environment) effects
Often, GWAS scans have generated lists of small p-values, many of which have failed to replicate. In some cases, SNPs that do replicate are ranked very low in the initial first stage scan, leading investigators to relax stringent alpha levels in order to reduce the chances of missing a true positive. We have recognized the need to develop creative ideas that can prioritize SNPs for further analysis. A reasonable approach is to use biological evidence to rank SNPs through an approach such as the weighted FDR (10), or though semi-empirical Bayes approaches (11, 12) . We have developed this idea further by incorporating prior knowledge in a fully Bayesian variable selection method. This approach allows tests for association to be conducted in a multivariate analysis (so independent main effects can be discovered), with priors used to help steer the algorithm towards more biologically plausible models (so that not all possible interactions need to be tested). A full Bayesian treatment also addresses multiple comparisons issue gracefully. A grant application that we are currently developing will propose the use of gene-expression data towards defining pathway modules. Pathway modules will aid our novel algorithm when applied on our stage 1 African American GWAS dataset.
Key Research Accomplishments
 Completing the largest single stage 1 genome-wide association study in any racial/ethnic population using the Illumina 1M technology.  Identifying a select set of top associations with breast cancer risk and collaborators willing to assist in replicating findings.  Conducting a large-scale multiethnic fine-mapping analysis of known breast cancer loci.  Contributing to the development and application of novel analytic methods for combining GWAS and admixture-scan data in the admixed African American population.
Conclusion
The stage 1 analyses have presented many exciting findings that we are actively pursuing through collaboration with new investigators with studies of breast cancer in African Americans. We are also working with many investigators leading GWAS of breast cancer in populations of European ancestry. It is clear that groups need to work together in the discovery phase as we are trying to identify risk variants with subtle effects on disease risk and very large sample sizes are needed. Together these largescale meta-analyses and replication efforts have great potential to reveal novel risk loci for breast cancer.
A future direction of our work will be to combine the GWAS data for multiple minority populations (as we have done for the chromosome 2 locus except genome-wide) as part of the NCI-supported Post-GWAS effort. Given our large scan in African American women, we hope to be in a position to lead this effort.
Revealing the genetic causes of breast cancer in each population will in time translate into more targeted preventive measures and treatment strategies for those at risk of developing the breast cancer.
